Follow-On Proteins May Present Problem For Post-Marketing Surveillance
Executive Summary
Post-marketing surveillance may prove ineffective in detecting emerging safety issues for follow-on proteins, participants suggested at the FDA/Drug Information Association Scientific Workshop on Follow-on Protein Pharmaceuticals